Kasiske B L, Lakatua J D
Department of Medicine, University of Minnesota College of Medicine, Hennepin County Medical Center, MN 55415, USA.
Miner Electrolyte Metab. 1997;23(3-6):296-300.
There have been a large number of clinical trials and two meta-analyses attempting to determine if dietary protein restriction retards the rate of renal disease progression. Indeed, in a systematic search of prospective, controlled trials examining the effects of protein restriction over at least 6 months, we located 23 published between 1980 and 1996. Only 12 of these trials were randomized and controlled. The results of the 23 studies were heterogeneous. Two meta-analyses combined the results of randomized, controlled trials. Although both meta-analyses concluded that dietary protein restriction significantly reduced the number of patients who died or required treatment for end-stage renal disease, the well-known effects of protein restriction on the signs and symptoms of uremia leave open the question of whether protein restriction had a substantial effect on renal disease progression per se. Adding to the uncertainty is the inconclusive result of the largest, best-designed clinical trial, the Modification of Diet in Renal Disease Study. In any case, the effect of protein restriction on the rate of decline in renal function is arguably modest, making it difficult to demonstrate statistical significance, even in large, well-designed clinical trials. All of these trials suggest that we need therapies that are more effective than dietary protein restriction to halt the progression of renal disease.
已有大量临床试验和两项荟萃分析试图确定饮食蛋白质限制是否会延缓肾病进展速度。事实上,在对至少为期6个月的蛋白质限制效果进行前瞻性对照试验的系统检索中,我们找到了1980年至1996年间发表的23项研究。其中只有12项试验是随机对照试验。这23项研究的结果并不一致。两项荟萃分析综合了随机对照试验的结果。尽管两项荟萃分析均得出结论,饮食蛋白质限制显著减少了死于终末期肾病或需要接受治疗的患者数量,但蛋白质限制对尿毒症体征和症状的众所周知的影响,使得蛋白质限制本身是否对肾病进展有实质性影响这一问题仍未解决。最大、设计最完善的临床试验——肾病饮食改良研究的不确定结果,更是增加了这种不确定性。无论如何,蛋白质限制对肾功能下降速度的影响可以说是适度的,即使在大型、设计良好的临床试验中,也很难证明其具有统计学意义。所有这些试验都表明,我们需要比饮食蛋白质限制更有效的疗法来阻止肾病的进展。